Cite
HARVARD Citation
DesRochers, T. et al. (n.d.). INNV-33. FUNCTIONAL EX VIVO TESTING PROSPECTIVELY IDENTIFIES NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS SENSITIVE TO TEMOZOLOMIDE TREATMENT IRRESPECTIVE OF MGMT METHYLATION STATUS. Neuro-oncology. pp. vii148-vii149. [Online].